title: Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
abstract: BACKGROUND
  Randomized trials supported the use of androgen deprivation therapy (ADT) with radiation therapy (RT) for intermediate-risk prostate cancer. However, the value of concurrent ADT was less certain with dose-escalated RT. Better methods of stratifying patients in this risk group may help select patients who are most likely to benefit.
  
  
  METHODS
  A total of 238 men with intermediate-risk (prostate specific antigen [PSA] 10-20, Gleason 7, or stage T2b-c) adenocarcinoma of the prostate were treated with external beam RT between 1989 and 2006. Patients had Gleason< or =6 (39%) or 7 (61%) tumors; median PSA was 10.5 ng/mL. A median of 37.5% of biopsy cores were positive from a median of 9 biopsy cores sampled. The median RT dose was 74 Gy to the prostate. A total of 112 patients (47%) received neoadjuvant and concurrent ADT (median, 4 months). Median follow-up period was 49 months.
  
  
  RESULTS
  The freedom from biochemical failure (FFBF, nadir + 2 definition) was 93% at 3 years, 86% at 4 years, and 80% at 5 years. On univariate analysis, the only factor associated with FFBF was percentage of positive cores (PPC, P = .0340). The prognostic value of PPC> or =50 was not evident in patients receiving ADT (FFBF at 4 years 90% vs 91%, P = .3015). For patients not receiving ADT, the impact of PPC> or =50 (FFBF at 4 years 76% vs 93%, P = .0844) was more pronounced. On multivariate analysis, PPC (P = .0388) was significantly associated with FFBF, whereas Gleason sum, ADT, RT dose, PSA, and T-stage were not.
  
  
  CONCLUSIONS
  After dose-escalated external beam RT, intermediate-risk prostate cancer patients with PPC> or =50 had the highest risk for biochemical failure and may be most likely to derive a benefit from ADT.
authors.affiliation: Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA. sliauw@radonc.uchicago.edu
authors.forename: Stanley L
authors.initials: SL
authors.lastname: Liauw
authors.forename: Janine
authors.initials: J
authors.lastname: Fricano
authors.forename: David
authors.initials: D
authors.lastname: Correa
authors.forename: Ralph R
authors.initials: RR
authors.lastname: Weichselbaum
authors.forename: Ashesh B
authors.initials: AB
authors.lastname: Jani
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy*; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen